Tocagen Inc

Tocagen — Forte Biosciences — Technical Presentation (June 2025)

33 slides from Tocagen's technical presentation, Jun 23, 2025

  1. Slide 1: FB102 Celiac Disease Phase 1b Results

    Exhibit 99.2 FORTE BIOSCIENCES FB102 CELIAC DISEASE PHASE 1B RESULTS JUNE 2025 1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securitie

  3. Slide 3: Clinical Stage FB102

    CLINICAL STAGE FB-102 • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK and T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL- 15 induced proliferati

  4. Slide 4: Alignment of Disease Biology and Mechanism for FB102

    ALIGNMENT OF DISEASE BIOLOGY AND MECHANISM FOR FB102 HIGHLIGHTS “PIPELINE-IN-A-PRODUCT” POTENTIAL FOR FB102 IN AUTOIMMUNE DISEASES WITH HIGH UNMET NEED Disease Species Outcome Reference Celiac disease Mouse Improved IL-15-induced PNAS, 2009 mucosal damage Vitiligo Mouse Enhanced repigmentation Sci T

  5. Slide 5: CD122 Antagonist Mechanism

    FB102 CD122 ANTAGONIST MECHANISM 5

  6. Slide 6: Clinical Stage FB102 Overview

    CLINICAL STAGE FB102 OVERVIEW CD122 is a subunit of the intermediate affinity IL-2/IL- 15 receptor expressed on NK cells, certain T cell subtypes and is a subunit of the high affinity IL-2 receptor expressed on Tregs FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL

  7. Slide 7: Inhibits IL-2/IL-15 CD4+ and CD8+ T Cell Activation In Vitro

    FB102 INHIBITS IL-2/IL-15 CD4+ AND CD8+ T CELL ACTIVATION IN IN VITRO DISEASE MODEL CD4+ and CD8+ T cells were treated with IL2 for 24 hours then with IL15 for 24 hours, simulating disease activity in the presence or absence of FB102 FB102 provides nearly complete inhibition of T cell activation CD8

  8. Slide 8: Celiac Disease

    CELIAC DISEASE 8

  9. Slide 9: No Approved Therapies for Celiac Disease

    NO APPROVED THERAPIES FOR CELIAC DISEASE; POTENTIAL FOR A SIGNIFICANT MARKET OPPORTUNITY ¡ Celiac disease is an autoimmune disease that’s triggered by consuming gluten and results in damage to the small intestine ¡ Symptom include diarrhea, fatigue, headaches, anemia, nausea, dermatitis herpetiformi

  10. Slide 10: IL-2 and IL-15 in Celiac Disease

    IL-2 AND IL-15 IN CELIAC DISEASE (CED) IL-2 ¡ Clear genetic basis for involvement of IL-2 in CeD ¡ Gluten-induced IL-2 production differentiates true CeD from non-gluten induced GI symptoms ¡ IL-2 strongly correlates with symptom severity and Serum IL-2 peaks within 4 hours after gluten exposure ¡ I

  11. Slide 11: Blocks Gluten-Induced Intestinal Damage by Blocking IL-2 and IL-15

    FB102 BLOCKS GLUTEN-INDUCED INTESTINAL DAMAGE IN CELIAC SUBJECT BY BLOCKING IL-2 AND IL-15 ACTIVATION OF CD8+ T CELLS healthy epithelium damaged epithelium + CD8+ CD8 cells T cell IL-15 damage epithelium FB102 blocks IL-15 and IL-2 IL-2 Gluten APC with specific gluten + CD4 T cell peptide lamina pro

  12. Slide 12: Blocks Both IL-2 and IL-15 Versus Other Celiac Drugs

    FB102 BLOCKS BOTH IL-2 AND IL-15, PROVIDING POTENTIAL ADVANTAGES OVER OTHER DRUGS BEING CLINICALLY INVESTIGATED FOR CELIAC DISEASE Immunomodulators Gluten Modification Immunotolerance Gut Healing Single targeting Multi targeting IMGX-003 CNP-101/TAK-101 IMU-856 IL-15 à CALY-002 CD122 (IL-2/IL-15)àFB

  13. Slide 13: Morphologic and Histological Measurements in Celiac Disease

    CELIAC DISEASE MORPHOLOGIC AND HISTOLOGICAL MEASUREMENTS IN CELIAC DISEASE 13

  14. Slide 14: Intraepithelial Lymphocytes Mediate Damage to Villi

    INTRAEPITHELIAL LYMPHOCYTES ARE MEDIATORS OF DAMAGE TO VILLI IN CELIAC DISEASE • Intraepithelial lymphocyte (IELs) are CD3+T cells that infiltrate the villus upon gluten challenge in celiac disease leading to villus atrophy • IEL count is measured as a density of CD3+ T cells per 100 enterocytes • S

  15. Slide 15: Villus Height to Crypt Depth Ratio (Vh:Cd)

    VILLUS HEIGHT TO CRYPT DEPTH RATIO (VH:CD) • Villus height to crypt depth (Vh:Cd) ratio measures morphological damage due to IEL infiltration after gluten exposure in celiac disease • Vh:Cd ratio in patients with CeD is ~2.0-3.0 when the patients are on Gluten Free Diet Adelman DC, Am J Gastroentero

  16. Slide 16: Composite Histological Scale for Celiac Disease

    COMPOSITE HISTOLOGICAL SCALE FOR CELIAC DISEASE Findings: A composite scale VCIEL comprising individual subject values for Vh:Cd and IEL with equal weighting appears to offer better accuracy and statistical precision, particularly for population analysis in clinical trials, as well as potentially of

  17. Slide 17: Phase 1b Celiac Disease Study

    FB102 PHASE 1B CELIAC DISEASE STUDY 17

  18. Slide 18: Celiac Disease Phase 1b Design

    CELIAC DISEASE PHASE 1B DESIGN • 32 subjects were enrolled at 9 sites (AUS/NZ) • Randomized 3:1 to FB102 vs PBO (24:8) • Subjects received 3 of 4 doses of either FB102 (10mg/kg) or placebo then began 16 day gluten challenge (2g,4g, 8g for 14 days) th • 4 dose of either FB102 or placebo on day 22 • E

  19. Slide 19: Baseline Demographics

    BASELINE DEMOGRAPHICS Placebo FB102 Overall Parameter N=8 N=24 N=32 Age (Years) Mean 38.3 40.8 40.1 Female 5 (62.5%) 19 (79.2%) 24 (75.0%) Sex [n (%)] Male 3 (37.5%) 5 (20.8%) 8 (25.0%) Hispanic or Latino 0 0 0 Not Hispanic or Latino 7 (87.5%) 23 (95.8%) 30 (93.8%) Ethnicity [n (%)] Not Reported 1 (

  20. Slide 20: Demonstrates Significant Benefit in Phase 1b Celiac Study

    FB102 DEMONSTRATES SIGNIFICANT BENEFIT IN PHASE 1B CELIAC DISEASE STUDY 20

  21. Slide 21: Statistically Significant Composite Histology (VCIEL) Benefit vs Placebo

    FB102 DEMONSTRATES STATISTICALLY SIGNIFICANT COMPOSITE HISTOLOGY (VCIEL) BENEFIT COMPARED TO PLACEBO Day 32 vs baseline VCIEL composite score –1.849 for PBO compared to 0.079 for FB102 treated subjects (p=0.0099) 21

  22. Slide 22: Statistically Significant Difference in IEL Density Change

    FB102 DEMONSTRATES STATISTICALLY SIGNIFICANT DIFFERENCE IN CHANGE IN IEL DENSITY COMPARED TO PLACEBO Day 32 vs baseline mean IEL density increase of 13.3 for PBO compared to a decrease of 1.5 for FB102 treated subjects (p=0.0035) 22

  23. Slide 23: Vh:Cd Ratio Improvement for FB102 vs Placebo

    VH:CD RATIO IMPROVEMENT OBSERVED FOR FB102 VS PLACEBO Day 32 vs baseline Vh:Cd ratio improvement of 73% for FB102 (-0.046) compared to PBO (-0.173) 23

  24. Slide 24: Gluten Challenge Symptom Benefit vs Placebo

    FB102 DEMONSTRATED GLUTEN CHALLENGE SYMPTOM EVENT BENEFIT VS PLACEBO Gluten challenge (GC) symptoms reported in patient diaries/AE collection GC induced GI symptoms tracked: nausea, diarrhea, vomiting, abdominal pain, abdominal bloating Through the 16 day gluten challenge FB102 demonstrated a 42% sy

  25. Slide 25: Phase 1b Celiac Disease Study Safety Summary

    FB102 PHASE 1B CELIAC DISEASE STUDY SAFETY SUMMARY 25

  26. Slide 26: Generally Safe and Well Tolerated: Adverse Events by Grade

    FB102 GENERALLY SAFE AND WELL TOLERATED Treatment Emergent Adverse Events By Grade Placebo (N=8) FB102 (N=24) Overall (N=32) n (Participant n (Participant n (Participant % % % Count) Count) Count) All Any Grade 8 100.0% 23 95.8% 31 96.9% Grade 1 (Mild) 8 100.0% 22 91.7% 30 93.8% Grade 2 (Moderate) 6

  27. Slide 27: Generally Safe and Well Tolerated: Adverse Events by Organ Class

    FB102 GENERALLY SAFE AND WELL TOLERATED Treatment Emergent Adverse Events By Organ Class Placebo (N=8) FB102 (N=24) Overall (N=32) n (Participant n (Participant n (Participant System Organ Class Summary % % % Count) Count) Count) Participants with at least one TEAE 8 100.0% 23 95.8% 31 96.9% Gastroi

  28. Slide 28: Celiac Disease FB102 Phase 2 Trial Overview

    CELIAC DISEASE FB102 PHASE 2 TRIAL OVERVIEW 28

  29. Slide 29: Celiac Disease Phase 2 Design

    CELIAC DISEASE PHASE 2 DESIGN • 14 sites AUS/NZ initially • Initiation in 2H25 • US IND expected late 2025/early 2026 • Topline data readout expected in 2026 29

  30. Slide 30: Development Timelines

    DEVELOPMENT TIMELINES 30

  31. Slide 31: Proposed Clinical Development Timeline

    FB102 PROPOSED 12 MONTH CLINICAL DEVELOPMENT Celiac Disease Vitiligo Phase 1b Phase1b Study Initiation 3Q24 Initiated 1H25 Positive Topline readout in June 2025 Topline data expected 1H26 Phase 2 Phase 2 Initiation 2H25 Initiation 2026 Topline data expected in 2026 Alopecia Areata Type 1 Diabetes Ph

  32. Slide 32: Summary

    SUMMARY 32

  33. Slide 33: Clinical Stage FB102 Summary

    CLINICAL STAGE FB-102 • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK and T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL- 15 induced proliferati

Forte Biosciences — Technical Presentation (June 2025) on 6ix